Multisystem Processes & Disorders

Osteomyelitis: workup and antibiotic duration

Clinical Overview and When to Suspect Osteomyelitis

— Hematogenous: monomicrobial, often S. aureus; vertebral bodies in adults, long-bone metaphysis in children

— Contiguous spread: post-trauma, post-surgical (hardware), or adjacent soft tissue infection

— Vascular insufficiency: diabetic foot ulcers, peripheral arterial disease — polymicrobial

— Diabetic with a non-healing foot ulcer >2 cm or present >1–2 weeks, especially if probe-to-bone positive

— IV drug user with focal back pain, fever, elevated inflammatory markers → vertebral osteomyelitis until proven otherwise

— Sickle cell patient with bone pain and fever (think Salmonella > S. aureus)

— Post-orthopedic hardware patient with wound drainage, sinus tract, or persistent pain beyond expected recovery

— Child with refusal to bear weight, point tenderness over metaphysis, fever

— Pressure ulcer (sacral/heel) Stage IV with exposed bone

— Many patients present to outpatient clinic with subtle findings; missing the diagnosis leads to chronic osteomyelitis with sequestrum, amputation, or sepsis

— Antibiotic duration is measured in weeks, not days — early correct diagnosis prevents under-treatment

— Diabetes, PAD, IVDU, hemodialysis, immunosuppression, recent bacteremia (especially S. aureus), prior orthopedic hardware, sickle cell disease, decubitus ulcers

Definition: infection of bone — cortex, marrow, or both — that can be acute (<2 weeks), subacute, or chronic (>6 weeks with necrotic bone/sequestrum).

Pathogenesis routes — three classic mechanisms drive the workup:

When to suspect on Step 3:

Why it matters for ambulatory Step 3 thinking:

Risk factors to elicit:

Board pearl: Any patient with persistent or recurrent S. aureus bacteremia must be evaluated for endocarditis and occult osteomyelitis (vertebral or hardware) — get an MRI if back pain is present, even mild. Failure to do so is a classic Step 3 distractor leading to relapse weeks later.

Presentation Patterns and Key History

— Sudden focal bone pain, fever, malaise, decreased range of motion

— Children: limp, pseudoparalysis, refusal to use limb; metaphysis of femur/tibia most common

— Adults: vertebral column predominates — insidious back pain worse at night, not relieved by rest, often without fever in 50%

— Lumbar > thoracic > cervical

— History clues: recent UTI, endocarditis, hemodialysis catheter, IVDU, recent spine procedure

— Red flags: progressive neurologic deficit, bowel/bladder dysfunction → epidural abscess

— Post-traumatic open fracture, post-surgical wound dehiscence, sinus tract drainage

— Pain disproportionate to wound appearance, low-grade fever, persistent drainage

— Chronic ulcer that fails to heal despite offloading and wound care for >2 weeks

— "Sausage toe" (diffuse erythematous swelling of a single digit) is highly suggestive

— Frequently afebrile with normal WBC — neuropathy masks pain; rely on inflammatory markers and imaging

— Draining sinus tract (pathognomonic when present), intermittent flares, sequestrum on imaging

— Long-standing chronic drainage raises risk of Marjolin ulcer (SCC arising in sinus tract)

— Duration of symptoms, prior antibiotic exposure (alters culture yield), prior similar episodes

— Hardware presence and date of implantation (early ≤3 mo vs delayed 3–24 mo vs late >24 mo prosthetic joint infection)

— Exposures: cat/dog bite (Pasteurella), puncture through sneaker (Pseudomonas), unpasteurized dairy/travel (Brucella), TB risk factors (Pott disease)

Acute hematogenous osteomyelitis:

Vertebral osteomyelitis (spondylodiscitis):

Contiguous-focus osteomyelitis:

Diabetic foot osteomyelitis:

Chronic osteomyelitis:

Key historical elements to extract:

Key distinction: Mechanical back pain improves with rest and worsens with activity; infectious back pain is constant, often nocturnal, and accompanied by elevated ESR/CRP. This distinction drives whether to image with MRI in the outpatient setting.

Physical Exam Findings and Systemic Assessment

— Point tenderness over involved bone (most sensitive physical finding)

— Erythema, warmth, swelling — may be subtle or absent in deep infections (vertebral, pelvic)

— Sinus tract with purulent drainage in chronic disease

— Limited range of motion at adjacent joint; sympathetic effusion possible

— Inspect every interdigital space, plantar surface, heel; remove socks and shoes

— Probe-to-bone (PTB) test: sterile blunt probe touches gritty bone through ulcer base — sensitivity ~60%, specificity ~90% in high-prevalence settings; positive PTB + elevated ESR strongly supports osteomyelitis

— Assess pedal pulses, capillary refill, monofilament sensation, ankle-brachial index if PAD suspected

— Ulcer size >2 cm² and depth >3 mm independently predict underlying osteomyelitis

— Focal spinal percussion tenderness, paraspinal muscle spasm

— Full neurologic exam: motor, sensory, reflexes, saddle anesthesia, rectal tone — any deficit mandates emergent MRI to rule out epidural abscess

— Vital signs: fever may be absent in chronic or diabetic disease

— SIRS criteria, qSOFA — sepsis warrants admission and empiric broad coverage

— Look for embolic stigmata (Janeway, Osler, splinter hemorrhages) → endocarditis as source of hematogenous seeding

— Skin: IVDU track marks, pressure ulcers, surgical scars

— Cardiac auscultation for new murmur (endocarditis seeding bone)

— Dental exam (oral flora seeding in vertebral disease)

— Indwelling catheters/ports as bacteremia source

Local findings:

Diabetic foot examination — structured approach:

Vertebral osteomyelitis exam:

Systemic/hemodynamic assessment:

Source hunt:

Step 3 management: A diabetic foot ulcer with positive probe-to-bone + ESR >70 mm/hr has post-test probability of osteomyelitis high enough to warrant empiric treatment and imaging confirmation — do not delay antibiotics waiting for biopsy in the septic patient, but obtain cultures first whenever the patient is clinically stable.

Diagnostic Workup — Initial Labs and Imaging

— CBC with differential: leukocytosis variably present; normal WBC does not exclude osteomyelitis (especially diabetic/chronic)

— ESR and CRP: cornerstone screening tests — ESR >70 mm/hr in diabetic foot ulcer has LR+ ~11 for underlying osteomyelitis; CRP rises and falls faster, useful for monitoring response to therapy

— Blood cultures × 2 sets before antibiotics: positive in ~50% of hematogenous/vertebral cases — can obviate need for bone biopsy if organism identified

— Comprehensive metabolic panel, HbA1c (glycemic optimization affects healing), procalcitonin (limited role)

— HIV testing if risk factors; consider TB workup (IGRA, CXR) if vertebral disease with subacute course

— Cheap, fast, screens for fracture, gas, foreign body, alternative diagnoses

— Findings lag clinical disease by 10–14 days: periosteal reaction, lytic lesions, cortical destruction, sequestrum/involucrum in chronic disease

— Normal x-ray does NOT exclude early osteomyelitis

— Sensitivity ~90%, specificity ~80%; detects marrow edema within 3–5 days

— Best for vertebral disease, diabetic foot, suspected epidural/paraspinal abscess

— Contraindications: non-MRI-compatible hardware, severe renal disease limiting gadolinium

— CT: better for cortical detail, sequestrum, surgical planning

— Three-phase bone scan: sensitive but nonspecific; useful when MRI contraindicated

— Tagged WBC scan or WBC/SPECT-CT: improves specificity in hardware-associated infection

— PET-CT: emerging role for chronic and prosthetic joint infection

Initial laboratory studies:

Plain radiographs — always first imaging:

MRI with and without contrast — gold standard imaging:

Alternative imaging when MRI not feasible:

Board pearl: CRP normalizes faster than ESR — trending CRP weekly is the preferred biomarker to confirm response to antibiotic therapy. Failure of CRP to fall by ~50% in 2–4 weeks suggests inadequate source control, resistant organism, or wrong diagnosis.

Diagnostic Workup — Confirmatory Studies and Microbiology

— Required to confirm diagnosis and tailor antibiotics in most non-bacteremic cases

— Image-guided percutaneous biopsy (CT or fluoroscopy) preferred; open biopsy if percutaneous nondiagnostic

— Send for: aerobic/anaerobic cultures, AFB, fungal cultures, histopathology, and (when indicated) 16S rRNA PCR

— Hold antibiotics ≥48 hours (ideally 2 weeks) before biopsy in stable patients to maximize culture yield

— Positive blood culture with typical pathogen (e.g., S. aureus) and concordant imaging — treat empirically based on blood isolate

— Hemodynamically unstable septic patient → start empirics, biopsy later if needed

— Superficial wound swabs and sinus tract cultures are unreliable — they reflect colonization, not deep bone pathogen, except when S. aureus is isolated (modest concordance)

— Always pursue deep tissue or bone for definitive microbiology

— Adults overall: S. aureus (MSSA/MRSA) dominant

— Diabetic foot: polymicrobial — S. aureus, streptococci, gram-negatives, anaerobes

— IVDU/hemodialysis: S. aureus, gram-negatives, occasional Pseudomonas

— Sickle cell: Salmonella > S. aureus

— Prosthetic joint (delayed): coagulase-negative staph, Cutibacterium acnes (shoulder)

— Cat/dog bite: Pasteurella multocida; human bite: Eikenella corrodens

— Plantar puncture through sneaker: Pseudomonas aeruginosa

— Vertebral with travel/dairy exposure: Brucella; subacute with risk factors: M. tuberculosis (Pott)

— TTE/TEE if S. aureus bacteremia or vertebral osteomyelitis to rule out endocarditis as source

Bone biopsy — the diagnostic gold standard:

When biopsy can be deferred:

Cultures to avoid:

Typical pathogens by clinical scenario:

Echocardiography:

CCS pearl: On CCS, the correct sequence is blood cultures × 2 → MRI → image-guided bone biopsy → targeted antibiotics. Starting vancomycin before cultures in a stable patient is a frequent CCS error that costs points; reserve empirics for septic or rapidly progressive presentations.

Risk Stratification and Management Logic

— Is the patient hemodynamically stable?

— Is there an organism identified (blood or bone culture)?

— Is surgical debridement or hardware removal needed?

— Obtain blood cultures, ESR/CRP, plain films

— MRI and bone biopsy BEFORE antibiotics when possible

— Start pathogen-directed therapy once cultures return

— Admit, blood cultures × 2, broad empiric IV antibiotics (vancomycin + antipseudomonal beta-lactam, e.g., cefepime or pip-tazo)

— Source control: surgical washout, abscess drainage, hardware exchange as needed

— Narrow once cultures return

— Necrotic bone, sequestrum, abscess, sinus tract requiring debridement

— Spinal instability, epidural abscess with neurologic compromise

— Infected hardware (often requires removal or staged exchange)

— Failure of medical therapy at 4–6 weeks (rising CRP, persistent symptoms)

— Mild/moderate without abscess or extensive necrosis: consider antibiotics alone for 6 weeks

— With necrotic bone or failed medical therapy: surgical resection of infected bone may shorten antibiotic course to 1–2 weeks post-resection

— Address vascular supply (ABI, revascularization referral) and offloading

— Historically all IV; recent OVIVA trial (2019) showed oral antibiotics non-inferior to IV for bone/joint infection when oral options have good bioavailability (fluoroquinolones, linezolid, TMP-SMX, clindamycin) and pathogen is susceptible

— Decision driven by bioavailability, GI absorption, and adherence — not by tradition

Decision framework — three core questions drive management:

Stable patient with suspected osteomyelitis (most outpatient cases):

Unstable/septic patient:

Surgical indications — consult orthopedics/neurosurgery:

Diabetic foot osteomyelitis — special pathway:

Route of antibiotic therapy:

Step 3 management: A clinically stable patient with confirmed osteomyelitis and a susceptible organism can often be discharged on oral high-bioavailability antibiotics with weekly outpatient follow-up, ESR/CRP monitoring, and ID clinic linkage — saves OPAT line complications and costs.

Pharmacotherapy — First-Line Antibiotic Regimens

— Vancomycin 15–20 mg/kg IV q8–12h (target AUC 400–600) — covers MRSA, MSSA, streptococci

— Plus gram-negative coverage when indicated: cefepime 2 g IV q8h or piperacillin-tazobactam 4.5 g IV q6h

— Add anaerobic coverage (metronidazole or use beta-lactam/inhibitor) for diabetic foot, decubitus, bite wounds

— MSSA: nafcillin 2 g IV q4h, oxacillin 2 g IV q4h, or cefazolin 2 g IV q8h (preferred over vancomycin even if susceptible — better outcomes)

— MRSA: vancomycin IV, or daptomycin 6–8 mg/kg IV daily, or linezolid 600 mg PO/IV q12h (oral option, monitor for cytopenias, peripheral/optic neuropathy with prolonged use)

— Streptococci: penicillin G or ceftriaxone 2 g IV daily

— Enterobacterales: ceftriaxone, ertapenem; ESBL → carbapenem

— Pseudomonas aeruginosa: cefepime or ceftazidime + ciprofloxacin for synergy/oral step-down

— Anaerobes: metronidazole or clindamycin

— Salmonella (sickle cell): ceftriaxone or fluoroquinolone

— Pasteurella: amoxicillin-clavulanate

— Fluoroquinolones (cipro, levo) — excellent bone penetration, gram-negative coverage

— Linezolid — MRSA oral; limit duration due to toxicity

— TMP-SMX — MRSA, MSSA; renal dosing

— Clindamycin — MSSA, strep, anaerobes; check D-test for inducible resistance

— Rifampin — adjunctive for hardware/biofilm infections (never as monotherapy — rapid resistance); pair with companion drug

— Native bone: 6 weeks standard

— After complete surgical resection of infected bone (e.g., toe amputation in diabetic foot): 1–2 weeks of soft-tissue coverage may suffice

— Prosthetic joint retained: 3 months (hip) to 6 months (knee) with biofilm-active regimen

— Vertebral osteomyelitis: 6 weeks per IDSA trial data

Empiric therapy (organism unknown, awaiting cultures):

Pathogen-directed therapy — typical durations 4–6 weeks from last positive culture or surgical debridement:

Oral step-down options (high bioavailability):

Duration:

Board pearl: Rifampin is biofilm-active and essential for staphylococcal prosthetic joint or hardware-retained infection — always combined with a companion antibiotic (typically a fluoroquinolone for gram-negatives or with beta-lactam for staph). Monotherapy guarantees resistance within days.

Procedures, Source Control, and Hardware Management

— Removes necrotic bone (sequestrum), drains abscesses, obtains deep cultures

— Antibiotics alone cannot penetrate avascular necrotic bone — surgery is non-negotiable when sequestrum present

— Goals: viable bleeding bone margins, dead-space management (antibiotic beads, vascularized flap, Masquelet technique)

— Retention with debridement and antibiotic suppression (DAIR): indicated only if symptoms <3 weeks, stable implant, susceptible organism, intact soft tissue

— One-stage exchange: remove and replace hardware in single surgery — selected centers, susceptible organism

— Two-stage exchange (gold standard for chronic prosthetic joint infection): explant + antibiotic spacer → 6 weeks of IV antibiotics → reimplantation after CRP normalizes and aspirate negative

— Chronic suppressive oral antibiotics if patient unfit for surgery

— Most managed medically with image-guided biopsy

— Surgical indications: neurologic deficit, spinal instability, large epidural abscess, failure of medical therapy

— Decompressive laminectomy + drainage for epidural abscess with cord compromise — emergent neurosurgery consult

— Vascular assessment first — ABI, toe pressures; revascularize if ischemic before definitive surgery

— Resection of infected bone (e.g., partial ray amputation) often curative and shortens antibiotic duration

— Multidisciplinary team: podiatry, vascular surgery, ID, endocrine, wound care

— Hyperbaric oxygen: considered for refractory chronic osteomyelitis, especially after radiation; evidence modest

— Local antibiotic delivery: PMMA beads, calcium sulfate carriers for dead-space management

— Negative pressure wound therapy for soft-tissue defects after debridement

Surgical debridement — cornerstone of chronic and complex osteomyelitis:

Hardware-associated osteomyelitis — three strategies:

Vertebral osteomyelitis interventions:

Diabetic foot — limb-preserving approach:

Adjuncts:

CCS pearl: For prosthetic joint infection on CCS, the high-yield sequence is joint aspiration → blood cultures → orthopedic surgery consult → IV antibiotics after cultures obtained → two-stage revision. Ordering antibiotics before aspiration sterilizes cultures and is a documented points-loser.

Special Populations — Elderly and Renal/Hepatic Impairment

— Atypical presentations: afebrile, normal WBC, vague malaise, falls or confusion may dominate

— Vertebral osteomyelitis more common; back pain often dismissed as degenerative — low threshold for MRI when ESR/CRP elevated

— Polypharmacy increases interaction risk (warfarin–TMP-SMX, statin–fluoroquinolones, QT prolongation with fluoroquinolones + other QT drugs)

— Higher rates of C. difficile with prolonged antibiotic courses — prefer narrowest spectrum, shortest effective duration

— Vancomycin: dose by AUC monitoring; adjust interval for CrCl <50

— Daptomycin: extend interval to q48h if CrCl <30; monitor weekly CPK (myopathy risk)

— Cefepime: renal dose adjustment critical — cefepime neurotoxicity (encephalopathy, myoclonus, non-convulsive status) occurs with under-adjusted dosing in CKD, often misdiagnosed as stroke or delirium

— TMP-SMX: hyperkalemia, AKI risk; avoid with ACEI/ARB/spironolactone combos in elderly

— Fluoroquinolones: dose-adjust for CrCl <50; risk of QT prolongation, tendinopathy (exacerbated by concurrent steroids), aortic dissection in elderly with vascular disease

— Linezolid: no renal adjustment but watch serotonin syndrome with SSRIs and prolonged use thrombocytopenia (>14 days)

— Vancomycin dosing tied to dialysis schedule (typically post-HD)

— High rate of S. aureus bacteremia from access — always evaluate for endocarditis AND vertebral osteomyelitis when back pain present

— Consider tunneled line removal/exchange as source control

— Avoid or dose-reduce ceftriaxone in biliary obstruction (biliary sludge, pseudolithiasis)

— Linezolid and tigecycline caution with severe hepatic dysfunction

Elderly patients — distinct considerations:

Renal impairment dosing pearls:

Hemodialysis patients:

Hepatic impairment:

Step 3 management: In an elderly CKD patient on cefepime for osteomyelitis who develops new altered mental status, stop cefepime immediately and check renal function — cefepime neurotoxicity is reversible with dose reduction or drug discontinuation, but missed diagnosis leads to escalation to ICU and unnecessary stroke workup.

Special Populations — Pediatrics, Pregnancy, and Sickle Cell

— Usually acute hematogenous, long-bone metaphysis (distal femur, proximal tibia)

— Pathogens: S. aureus (including MRSA) dominant; Kingella kingae in <4 yo (fastidious — inoculate blood culture bottles)

— Group B strep and E. coli in neonates

— Children with sickle cell: Salmonella > S. aureus

— Workup: ESR/CRP, blood cultures, MRI, joint aspiration if effusion (rule out septic arthritis)

— Duration: modern pediatric data support 3–4 weeks total (IV transitioned to oral after clinical and CRP improvement, typically 3–7 days IV) — shorter than adult courses

— Empiric: cefazolin or nafcillin if low MRSA prevalence; add vancomycin/clindamycin where MRSA common

— Rare; when present, manage similarly with attention to antibiotic safety

— Safe in pregnancy: beta-lactams (penicillins, cephalosporins, carbapenems), clindamycin, vancomycin

— Avoid: fluoroquinolones (cartilage), tetracyclines (after 1st trimester — fetal teeth/bone), TMP-SMX (1st trimester neural tube; 3rd trimester kernicterus), linezolid (limited data), daptomycin (limited data)

— MRI without gadolinium preferred; gadolinium relatively contraindicated, especially 1st trimester

— Salmonella species cause majority of osteomyelitis (functional asplenia + bowel microinfarction)

— Empiric: ceftriaxone + vancomycin; tailor by culture

— Distinguish from vaso-occlusive crisis (VOC) — overlapping bone pain, fever, leukocytosis

— MRI helps differentiate bone infarct (geographic marrow edema) from osteomyelitis (often requires biopsy)

— Higher rates of MRSA, Pseudomonas, Candida osteomyelitis (vertebral, sternoclavicular, pubic symphysis)

— Always evaluate for endocarditis with TTE/TEE

— Address substance use disorder — medication for opioid use disorder (buprenorphine/methadone) improves treatment completion

Pediatric osteomyelitis:

Pregnancy:

Sickle cell disease:

IV drug users:

Key distinction: In a child <4 years old with subacute bone/joint symptoms, mild CRP elevation, and negative routine cultures, think Kingella kingae — order PCR on synovial fluid and inoculate blood culture bottles with joint aspirate to improve yield.

Complications and Adverse Outcomes

— Chronic osteomyelitis with sequestrum, involucrum, sinus tract formation — most common consequence of inadequate initial therapy

— Pathologic fracture through weakened bone

— Growth disturbance in pediatric patients with physeal involvement (limb length discrepancy, angular deformity)

— Septic arthritis from contiguous joint spread

— Soft tissue abscess, cellulitis, fasciitis

— Marjolin ulcer: squamous cell carcinoma arising in chronic draining sinus tract (typically >20 years) — biopsy any non-healing or new lesion

— Bacteremia, sepsis, septic shock

— Metastatic infection: endocarditis, septic pulmonary emboli, brain abscess (especially with S. aureus)

— Multi-organ failure in severe cases

— Epidural abscess → cord compression, paraplegia

— Psoas abscess, paraspinal abscess

— Vertebral collapse with kyphotic deformity (especially Pott disease)

— Permanent neurologic deficits if decompression delayed

— Progression to wet gangrene, necrotizing fasciitis

— Amputation — major amputation rates remain ~10–20% even with optimal care

— 5-year mortality after major amputation ~50%, comparable to many cancers

— OPAT line complications: catheter-related bloodstream infection, DVT, line dislodgment, mechanical failure

— C. difficile infection from prolonged antibiotics

— Drug toxicities: vancomycin AKI, daptomycin myopathy, linezolid cytopenias/neuropathy, fluoroquinolone tendinopathy and aortic events

— Antibiotic resistance from suboptimal dosing or duration

— Persistent or recurrent symptoms, failure of CRP to decline ≥50% by 4 weeks, new abscess or sinus tract, positive cultures despite therapy

— Triggers re-imaging, repeat biopsy, surgical reassessment

Local complications:

Systemic complications:

Vertebral-specific complications:

Diabetic foot complications:

Treatment-related complications:

Failure of therapy — defined as:

Board pearl: A patient with a decades-old chronic draining sinus tract that suddenly changes — new pain, new mass, bloody drainage — get a biopsy of the tract margin to rule out Marjolin ulcer (SCC) before assuming infectious flare. Missing this transformation is a classic vignette twist.

When to Escalate Care — ICU, Consult, and Admission Triage

— Sepsis, hemodynamic instability, inability to tolerate orals

— Neurologic deficit from suspected vertebral osteomyelitis

— Need for surgical debridement or hardware management

— Diabetic foot with deep abscess, gas, necrotic tissue, or systemic toxicity

— IVDU with concern for endocarditis or polymicrobial bacteremia

— Failure of outpatient therapy with worsening markers or imaging

— Septic shock requiring vasopressors

— Cord compromise pending emergent decompression

— Respiratory failure from septic pulmonary emboli

— Cefepime neurotoxicity with status epilepticus

— Infectious disease: virtually all cases benefit; mandatory for prosthetic joint, vertebral, multidrug-resistant, and OPAT planning. ID involvement improves outcomes and shortens stays.

— Orthopedic surgery: debridement, hardware, pediatric long-bone disease

— Neurosurgery/spine surgery: epidural abscess, spinal instability

— Vascular surgery: diabetic foot with PAD; revascularization before debridement

— Plastic surgery: soft-tissue coverage with flaps after debridement

— Endocrinology: glycemic optimization in diabetics

— Podiatry: offloading, custom footwear, ongoing wound care

— Pain management/addiction medicine: IVDU patients with active use disorder

— Hemodynamically stable, source identified, susceptible organism

— Reliable patient with ability to follow up weekly

— No surgical urgency

— Oral high-bioavailability options OR stable OPAT plan with home infusion service

— Discharge to SNF or home with PICC requires explicit antibiotic plan, duration, monitoring labs schedule, follow-up appointment

— Medication reconciliation: warfarin-antibiotic interactions, statin holds

Admit to hospital:

ICU admission:

Specialty consults — anticipate on Step 3:

Outpatient management appropriate when:

Transitions of care — high-risk handoffs:

Step 3 management: Any patient with vertebral osteomyelitis and new or progressive neurologic deficit requires emergent MRI of the entire spine (not just symptomatic level — multi-level abscesses occur in ~20%) and emergent neurosurgery consult. Don't waste time on plain films or CT first.

Key Differentials — Same-Category Bone/Joint Conditions

— Pain localized to joint with effusion, restricted ROM, often more dramatic erythema

— Joint aspiration: WBC >50,000/µL with PMN predominance, positive Gram stain/culture

— Can coexist with osteomyelitis (especially in children through transphyseal vessels in infants)

— Superficial erythema, warmth, lacks deep point bone tenderness

— Normal or mildly elevated inflammatory markers, no probe-to-bone, normal imaging

— Key distinction: cellulitis responds within 48–72 hours to appropriate antibiotics; persistent symptoms beyond this window mandate imaging for occult osteomyelitis or abscess

— Diabetic neuropathic joint with bone destruction, deformity, "rocker-bottom foot"

— Often confused with osteomyelitis radiographically — both show bone destruction

— MRI distinction: Charcot tends to involve midfoot (tarsometatarsal) with subchondral cysts and joint-centered changes; osteomyelitis centers on bone marrow with adjacent ulcer and sinus tract

— Charcot is typically warm with normal or only mildly elevated CRP in absence of infection

— Mimics osteomyelitis closely

— MRI may show similar marrow edema; diaphyseal involvement and bilateral symmetric pattern favor infarct

— Often requires biopsy or empiric trial with close monitoring

— Activity-related, point tenderness, MRI shows fracture line through marrow edema

— No systemic features, normal inflammatory markers

— Acute monoarticular, erythematous joint; tophi or chondrocalcinosis on imaging

— Crystals on aspirate

— Steroid use, sickle cell, alcohol; MRI shows characteristic "double-line sign"

— No infectious markers

— Primary (osteosarcoma, Ewing) or metastatic

— Persistent pain, mass, atypical imaging — biopsy clinches

Septic arthritis:

Cellulitis without bone involvement:

Charcot neuroarthropathy:

Bone infarction (sickle cell):

Stress fracture:

Gout/pseudogout:

Avascular necrosis (osteonecrosis):

Bone tumors:

Board pearl: In a diabetic with foot warmth, swelling, and bony changes but NO ulcer and normal inflammatory markers, the diagnosis is Charcot foot, not osteomyelitis — treat with offloading and total contact casting, not antibiotics. Antibiotics for Charcot is a frequent wrong-answer trap.

Key Differentials — Other-Category Causes

— Common confounder in vertebral osteomyelitis workup

— Pain improves with rest, worsens with activity; normal ESR/CRP

— Imaging shows degenerative changes without marrow edema or end-plate destruction

— Sudden onset after minimal trauma, elderly patient

— MRI shows fracture line, marrow edema confined to vertebral body, no disc involvement

— Key distinction from osteomyelitis: infection typically crosses the disc space involving two adjacent vertebrae and the intervening disc (discitis); compression fractures spare the disc

— History of malignancy or unintentional weight loss

— MRI: lesions in vertebral body and pedicles, often multiple non-contiguous levels, typically spares disc space

— PET-CT and tissue biopsy clinch diagnosis

— Lytic bone lesions, bone pain, anemia, hypercalcemia, renal failure

— SPEP/UPEP, free light chains, bone marrow biopsy

— Young adult, morning stiffness improving with activity, sacroiliac involvement, HLA-B27

— Inflammatory markers elevated but pattern and demographics differ

— Primary muscle abscess, often S. aureus; tropical climates, immunocompromised, IVDU

— MRI distinguishes from bone-centered infection

— Calf swelling, pain mimics lower extremity infection

— Doppler ultrasound differentiates

— Pain out of proportion, rapid progression, bullae, crepitus, systemic toxicity

— Surgical emergency — do not delay for imaging in clear clinical scenario

— Can present with bone pain from metastatic infection — must consider especially with S. aureus bacteremia

— Pain without infection signs; consider as alternative when ulcer is absent

Mechanical back pain / degenerative disc disease:

Vertebral compression fracture (osteoporotic):

Metastatic spinal disease:

Multiple myeloma:

Spondyloarthritis (ankylosing spondylitis):

Pyomyositis:

Deep vein thrombosis:

Necrotizing fasciitis:

Endocarditis with embolic phenomena:

Diabetic neuropathy / peripheral arterial disease ischemic pain:

Step 3 management: When MRI shows two adjacent vertebrae with destruction of the intervening disc space and end-plate erosion, this pattern is highly specific for infectious spondylodiscitis — proceed to biopsy and treat as osteomyelitis. Tumors classically spare the disc; this single imaging feature is the most useful discriminator.

Discharge Medications, Secondary Prevention, and Long-Term Plan

— Document specific agent, dose, route, planned duration, and end date

— For native osteomyelitis: typically 6 weeks total from last positive culture or definitive debridement

— Diabetic foot post-amputation with clear margins: 1–2 weeks of soft-tissue coverage

— Hardware-retained staphylococcal infection: prolonged with rifampin-based combination, often 3–6 months

— Vertebral: 6 weeks; longer if undrained abscess or Brucella/TB

— Weekly labs: CBC, BMP, CRP, drug-specific (vanc trough/AUC, CPK for dapto, LFTs)

— PICC line care education, signs of line infection

— Home health nursing coordination

— Per OVIVA, oral non-inferior to IV when bioavailability and susceptibility allow

— Reduces line complications, hospital readmission, cost

— Target A1c individualized but typically <8%; tight control delays wound healing if hypoglycemia results

— Coordinate with endocrinology/primary care

— Statin, antiplatelet, smoking cessation, BP and lipid management

— Vascular surgery follow-up if PAD identified

— Custom footwear, total contact casting, podiatry follow-up

— Daily foot self-exam education

— Initiate medication for opioid use disorder (buprenorphine, methadone) before discharge — improves antibiotic adherence and survival

— Connect to harm reduction services

— Pneumococcal, influenza, COVID-19 — especially diabetics, asplenic, elderly

— Td/Tdap if open wound history

— Patient education on warning signs: new drainage, increasing pain, fever

— Clear return precautions in writing

Antibiotic completion plan — clarity at discharge is critical:

OPAT considerations:

Oral step-down — favor when feasible:

Glycemic control in diabetics:

Vascular optimization:

Wound care and offloading:

Substance use treatment in IVDU patients:

Vaccinations review:

Recurrence prevention:

Board pearl: In hardware-retained staphylococcal osteomyelitis or prosthetic joint infection, rifampin-based combination therapy reduces relapse rates significantly because rifampin penetrates biofilm. Always pair with a companion drug (fluoroquinolone, beta-lactam, or linezolid) — and monitor for drug interactions (rifampin is a potent CYP3A4 inducer that lowers warfarin, OCP, statin, and many antiretroviral levels).

Follow-Up, Monitoring, and Rehabilitation

— Week 1–2: clinical assessment, labs (CBC, BMP, CRP, drug-specific monitoring)

— Week 4: repeat ESR/CRP — expect ≥50% reduction in CRP; failure prompts re-evaluation

— End of therapy (week 6): clinical reassessment, ESR/CRP, plain film if applicable

— 3 and 6 months post-therapy: monitor for relapse — most recurrences occur within first year

— Vancomycin: AUC or trough, weekly BMP for AKI

— Daptomycin: weekly CPK; hold if CPK >5× ULN or symptomatic

— Linezolid: weekly CBC for thrombocytopenia; neuro exam for peripheral/optic neuropathy with use >14–28 days

— Fluoroquinolones: watch for tendon pain (Achilles), QTc, glucose dysregulation in diabetics

— TMP-SMX: BMP for hyperkalemia and AKI; CBC for cytopenias

— Rifampin: LFTs, drug interactions

— Routine repeat MRI not required if clinically improving — marrow edema persists for months and can lag clinical recovery

— Repeat imaging only when worsening symptoms or failure to improve

— Physical therapy for deconditioning, gait retraining, prosthetic fitting after amputation

— Spine bracing if vertebral involvement until stability confirmed

— Occupational therapy for ADLs in elderly

— Realistic timelines: pain may persist weeks beyond antibiotic completion; bone remodeling takes months

— Activity restrictions and weight-bearing limits per surgeon

— Smoking cessation — nicotine impairs bone healing

— Nutrition: adequate protein, vitamin D, calcium

— Return of pain, new drainage, fever, new sinus tract, systemic symptoms

— Low threshold for early evaluation

— Diabetic foot patients: lifelong podiatry, annual foot exam minimum, recurrent ulcer prevention

— Pressure ulcer prevention in immobile patients (turning schedules, support surfaces)

Outpatient follow-up cadence:

Monitoring parameters by drug:

Imaging follow-up:

Rehabilitation:

Counseling topics:

Relapse warning signs (patient education):

Long-term considerations:

CCS pearl: On CCS, after starting targeted antibiotics for osteomyelitis, advance the clock to week 2 and reorder CRP — a falling CRP confirms response and supports continued therapy; a flat or rising CRP triggers re-imaging and surgical reassessment. This trending pattern is what graders look for in longitudinal management cases.

Ethical, Legal, and Patient Safety Considerations

— Patients must understand 6+ week duration, line complications, drug toxicities, and monitoring requirements

— Document discussion of OPAT versus oral alternatives where evidence supports either choice (post-OVIVA era)

— Shared decision-making with explicit patient preferences recorded

— Discharge to SNF, home with PICC, or outpatient IV infusion requires explicit, written plan: drug, dose, duration, monitoring schedule, follow-up appointments, emergency contacts

— Medication reconciliation: stop holds on home medications appropriately, address drug interactions (warfarin-TMP-SMX, rifampin-OCP/anticoagulants/statins, fluoroquinolone-QT meds)

— Confirm DME, home health, and infusion services are arranged BEFORE discharge — premature discharge without confirmed services is a sentinel event

— Avoid empiric broad-spectrum continuation when cultures support narrowing

— Document indication, duration plan, and stop date in every chart

— Recognize C. difficile risk with prolonged courses; use probiotics judiciously (limited evidence)

— Treat active addiction concurrently — do not condition antibiotic therapy on sobriety

— Initiate MOUD (buprenorphine/methadone) during admission

— Use of PICC in active IVDU: harm reduction approaches, supervised dosing, midline or oral alternatives when feasible

— Avoid stigmatizing language in documentation; provide non-discriminatory care

— Refusal of recommended amputation in diabetic foot osteomyelitis: assess decision-making capacity, ensure understanding of mortality risk, involve ethics if persistent disagreement; document thoroughly

— Patients may decline limb-saving surgery — respect informed refusal

— Report M. tuberculosis osteomyelitis (Pott disease) to public health

— Brucellosis is a nationally notifiable disease

— Diabetic foot amputation rates higher in Black and Hispanic populations and uninsured patients — recognize systemic barriers and ensure equitable access to vascular surgery, ID consultation, and multidisciplinary care

Informed consent for prolonged antibiotic therapy:

Transitions of care — highest-risk Step 3 scenario:

Patient safety — antimicrobial stewardship:

IV drug users — ethical complexity:

Capacity assessments:

Mandatory reporting and public health:

Disparities and access:

Step 3 management: When discharging an IVDU patient with osteomyelitis on a 6-week IV antibiotic course, harm reduction with supervised PICC or transition to high-bioavailability oral antibiotics is preferred over withholding therapy due to misuse concerns — denying treatment is neither ethical nor evidence-based. Document the shared decision-making.

High-Yield Associations and Rapid-Fire Clinical Facts

— Diabetic foot → polymicrobial, S. aureus + gram-negatives + anaerobes

— Plantar puncture through sneaker → Pseudomonas aeruginosa

— Sickle cell → Salmonella (still S. aureus common, but Salmonella is the buzz association)

— IVDU → S. aureus, Pseudomonas, Candida; vertebral, sternoclavicular, pubic symphysis

— Cat/dog bite → Pasteurella multocida

— Human bite → Eikenella corrodens

— Hemodialysis → S. aureus bacteremia from access

— Prosthetic joint, delayed → coagulase-negative staph, Cutibacterium acnes (shoulder)

— Travel, unpasteurized dairy → Brucella

— Pott disease → Mycobacterium tuberculosis, thoracic spine, gibbus deformity

— Children <4 yo → Kingella kingae (PCR, blood culture bottle inoculation)

— Plain films lag 10–14 days

— MRI most sensitive — marrow edema in 3–5 days

— Infectious spondylodiscitis crosses disc space; tumor spares it

— Sequestrum = necrotic bone; involucrum = new bone around it (chronic osteomyelitis)

— ESR >70 in diabetic foot ulcer → strongly suggests osteomyelitis

— CRP falls faster than ESR — use for treatment response

— Procalcitonin not well validated for osteomyelitis

— Sinus tract/swab cultures unreliable except for S. aureus

— Hold antibiotics 2 weeks before biopsy in stable patients

— Blood cultures positive in ~50% of vertebral cases

— MSSA: nafcillin/cefazolin > vancomycin

— Biofilm/hardware: add rifampin (never monotherapy)

— OVIVA: oral non-inferior to IV with high bioavailability + susceptibility

— Standard duration: 6 weeks native bone

— Diabetic foot post-resection: 1–2 weeks

— Pott disease: TB vertebral osteomyelitis, often thoracic

— Brodie abscess: subacute hematogenous osteomyelitis, walled-off, often tibia in children

— SAPHO syndrome: synovitis, acne, pustulosis, hyperostosis, osteitis

— CRMO: chronic recurrent multifocal osteomyelitis, autoinflammatory, pediatric

— Marjolin ulcer: SCC in chronic sinus tract

Pathogen-scenario links:

Imaging pearls:

Lab pearls:

Microbiology pearls:

Treatment pearls:

Eponyms/syndromes:

Board pearl: "S. aureus bacteremia + back pain" = vertebral osteomyelitis until MRI proves otherwise — this single association underlies a disproportionate share of Step 3 vignettes.

Board Question Stem Patterns

— Diabetic with non-healing foot ulcer, ESR 92, positive probe-to-bone → diagnose osteomyelitis; next step is MRI (if not yet done) or bone biopsy for organism identification before antibiotics

— IVDU with 3 weeks of progressive low back pain, fever 38.2, ESR 110, normal x-ray → vertebral osteomyelitis; next step MRI lumbar spine with contrast, then blood cultures and bone biopsy

— Sickle cell child with bone pain, fever, leukocytosis → most likely organism Salmonella; empiric ceftriaxone + vancomycin

— Child age 7 refuses to bear weight, fever, tender distal femur, elevated CRP → acute hematogenous osteomyelitis (S. aureus); MRI, blood cultures, empiric cefazolin or vancomycin

— Patient with prosthetic knee, indolent pain, low-grade fever, persistently elevated CRP → prosthetic joint infection; joint aspiration before antibiotics, orthopedic surgery consult, anticipate two-stage revision

— Post-operative spine patient with worsening back pain, new drainage at incision, fever → surgical site infection with possible vertebral osteomyelitis; MRI, surgical washout, cultures, IV antibiotics

— Plantar puncture wound through sneaker, now with localized pain and erythema → think Pseudomonas; empiric ciprofloxacin or antipseudomonal beta-lactam

— Diabetic foot with charcot deformity, no ulcer, mildly warm, normal CRP → Charcot, NOT osteomyelitis; offload with total contact cast

— Patient with chronic draining sinus from old osteomyelitis, new mass or bleeding → Marjolin ulcer (SCC); biopsy

— Sus S. aureus bacteremia from dialysis line, develops new back pain → vertebral osteomyelitis; MRI, TEE for endocarditis, prolonged IV antibiotics, line removal

— Treating empirically before obtaining cultures in a stable patient

— Using a wound swab to guide therapy (colonization, not deep pathogen)

— Stopping antibiotics at 2 weeks for native bone osteomyelitis (too short)

— Choosing vancomycin over cefazolin for confirmed MSSA (cefazolin/nafcillin superior)

— Rifampin monotherapy for hardware infection (rapid resistance)

— Antibiotics alone for Charcot foot

— Forgetting to evaluate for endocarditis in S. aureus bacteremia with bone involvement

Classic stems and the answer they're driving toward:

Common wrong-answer traps:

CCS pearl: The highest-yield CCS sequence is blood cultures × 2 → MRI → consult ID + ortho/neurosurg → bone biopsy → targeted antibiotics → trend CRP weekly → continue 6 weeks. Deviating from this sequence by ordering antibiotics before cultures or skipping biopsy in a stable patient costs points.

One-Line Recap

Osteomyelitis diagnosis hinges on inflammatory markers plus MRI plus bone biopsy in stable patients, and treatment requires pathogen-directed antibiotics for typically 6 weeks combined with source control whenever necrotic bone, abscess, or infected hardware is present.

— ESR/CRP + plain film as screen; MRI for confirmation

— Bone biopsy before antibiotics in stable patients — superficial swabs are unreliable

— Blood cultures × 2; consider echocardiogram if S. aureus bacteremia

— Pathogen-directed therapy for 6 weeks native bone; 1–2 weeks if completely resected (e.g., post-amputation with clean margins)

— MSSA → cefazolin or nafcillin (better than vancomycin)

— MRSA → vancomycin, daptomycin, or linezolid

— Hardware/biofilm → add rifampin (never monotherapy)

— OVIVA: oral non-inferior to IV when bioavailability and susceptibility allow

— Trend CRP weekly — expect ≥50% reduction by 4 weeks

— Debride necrotic bone, drain abscesses, manage hardware (DAIR vs one-stage vs two-stage exchange)

— Diabetic foot: vascular optimization, offloading, multidisciplinary team

— Vertebral with neurologic deficit → emergent decompression

— S. aureus bacteremia + back pain → vertebral osteomyelitis + endocarditis workup

— Sickle cell + bone pain → Salmonella

— Plantar puncture through sneaker → Pseudomonas

— Children <4 → Kingella kingae (PCR, blood culture bottles)

— Chronic sinus tract changing character → Marjolin ulcer (SCC)

— Diabetic foot, normal CRP, no ulcer, warm deformed foot → Charcot, not infection

Diagnostic essentials:

Treatment essentials:

Source control essentials:

Don't-miss associations:

Step 3 management: The exam rewards the candidate who gets cultures before antibiotics in stable patients, narrows therapy aggressively, transitions to high-bioavailability oral when feasible, coordinates multidisciplinary follow-up, and trends CRP to confirm response — these habits convert correct diagnosis into durable cure and exam points alike.